おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Navigenics
company
About
Navigenics is a personal genomics company that uses genetic testing to help people determine their individual risk for health conditions.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Genetics,Health Care,Pet
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Navigenics, Inc. helps educate and empower individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$43M
Navigenics has raised a total of
$43M
in funding over 2 rounds. Their latest funding was raised on
Feb 4, 2010 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 4, 2010 | Series C | $18M | 1 | — | — | Detail |
| Nov 7, 2007 | Series Unknown | $25M | 1 |
Sequoia Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Navigenics is funded by 2 investors.
Sequoia Capital
and Procter & Gamble Company
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Sequoia Capital
|
Yes | Series Unknown |
Procter & Gamble Company
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
